ASH News Daily 2013 - Day 3 - (Page B-17)

Now enrolling Investigating ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia Phase II Open-Label Study of the Efficacy and Safety of ABT-199 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Harboring the 17p Deletion N=100 ABT-199 is an investigational agent that has not been approved by regulatory agencies for the use under investigation in this trial. Primary Endpoint Secondary Endpoints * Overall response rate * * * * * * * * Complete remission rate Partial remission rate Duration of response Progression-free survival Time to progression Overall survival Percentage of patients who move on to stem-cell transplant Safety and tolerability of ABT-199 Key Inclusion Criteria * Adult patients ≥18 years of age * Diagnosis of CLL that meets 2008 IWCLL NCI-WG criteria (relapsed/refractory after receiving ≥1 prior line of therapy and 17p deletion) * ECOG performance score of ≤2 * Adequate bone marrow function * Adequate coagulation, renal, and hepatic function, per laboratory reference range To learn more about this study, please visit www.ClinicalTrials.gov. NCT#01889186 Reference: ClinicalTrials.gov. @ 2013 Genentech USA, Inc. All rights reserved. BIO0001961500 Printed in USA. 76202ha_e.indd 1 8/9/13 4:31 PM 

Table of Contents for the Digital Edition of ASH News Daily 2013 - Day 3

Table of Contents

ASH News Daily 2013 - Day 3

https://www.nxtbookmedia.com